Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDTYAF)

Drug Name

1-(5-chloro-2-hydroxy-4-nitrophenyl)-3-phenylurea Drug Info

Synonyms

CHEMBL430376; 1-(5-chloro-2-hydroxy-4-nitrophenyl)-3-phenylurea; 117745-34-3; Urea, N-(5-chloro-2-hydroxy-4-nitrophenyl)-N'-phenyl-; ACMC-20mnej; AC1MXJKZ; SCHEMBL4241814; CTK0G0114; DTXSID10396461; MolPort-001-764-839; ZX-AT026392; ZINC3917497; BDBM50203018; AKOS024384929; MCULE-2402836101; ST51035461; 3-(5-chloro-2-hydroxy-4-nitrophenyl)-1-phenylurea

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 3791448
CAS Number: CAS 117745-34-3
TTD Drug ID: DMDTYAF

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting C-X-C chemokine receptor type 2 (CXCR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[2]
Clotrimazole	DMMFCIH	Cutaneous candidiasis	1F23.14	Approved	[3]
Reparixin	DMVBA7I	Pancreatic islet transplantation failure	NE84	Phase 3	[2]
SCH-527123	DMPUAOE	Chronic obstructive pulmonary disease	CA22	Phase 2	[4]
SB-265610	DM8TKG5	Asthma	CA23	Phase 2	[5]
AZD-5069	DM3JSFK	Asthma	CA23	Phase 2	[6]
PS-938285	DMHZIFJ	Chronic obstructive pulmonary disease	CA22	Phase 2	[7]
GSK1325756	DMA6RBF	Chronic obstructive pulmonary disease	CA22	Phase 2	[8]
SB-656933	DMCY785	Chronic obstructive pulmonary disease	CA22	Phase 2	[9]
RIST4721	DMA3DKO	Hidradenitis suppurativa	ED92.0	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C chemokine receptor type 2 (CXCR2)	TT30C9G	CXCR2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1713-7.
2	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
3	Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
4	CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
5	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
6	Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
7	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
8	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
9	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
10	A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193.